Skip to content

Study · Non-randomized trial · n = 855 · 2016

5 results

Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.

Onishi Y, Oura T, Nishiyama H, Ohyama S, Takeuchi M, Iwamoto N

Endocrine journal23 Dec 2015Cited by 26 (Europe PMC)

PMID26698689 (opens in a new tab)DOI10.1507/endocrj.ej15-0518 (opens in a new tab)PepBankPUB-26698689
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese T2D patients, dulaglutide improved HbA1c regardless of patient characteristics.

    In plain wordsIn Japanese people with diabetes, HbA1c improved from baseline with dulaglutide across patient characteristics.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c improvement across characteristics
    Study

    n = 855

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · up to 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Once weekly dulaglutide 0.75 mg improved blood glucose control as measured by HbA1c regardless of patient characteristics; patients with higher baseline HbA1c values had greater improvements compared to patients with lower baseline values.

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In Japanese T2D patients receiving dulaglutide, higher baseline HbA1c was associated with greater HbA1c improvement than lower baseline HbA1c.

    In plain wordsIn Japanese patients receiving dulaglutide, those with higher initial HbA1c improved more than those with lower initial HbA1c.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c improvement by baseline HbA1c
    Study

    n: not reported in source

    Comparator
    Lower baseline HbA1c
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Once weekly dulaglutide 0.75 mg improved blood glucose control as measured by HbA1c regardless of patient characteristics; patients with higher baseline HbA1c values had greater improvements compared to patients with lower baseline values.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In Japanese T2D patients receiving dulaglutide, weight loss was greater with lower baseline HbA1c.

    In plain wordsIn Japanese patients receiving dulaglutide, those with lower initial HbA1c lost more weight than those with higher initial HbA1c.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight loss by baseline HbA1c
    Study

    n: not reported in source

    Comparator
    Higher baseline HbA1c
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Weight loss was greater in patients with lower baseline HbA1c and in patients taking concomitant biguanides.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In Japanese T2D patients receiving dulaglutide, weight loss was greater with concomitant biguanides than without them.

    In plain wordsIn Japanese patients receiving dulaglutide, those taking biguanides lost more weight than those not taking biguanides.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight loss with biguanides
    Study

    n: not reported in source

    Comparator
    Without concomitant biguanides
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Weight loss was greater in patients with lower baseline HbA1c and in patients taking concomitant biguanides.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    In Japanese T2D patients receiving dulaglutide, concomitant sulfonylurea use had the greatest effect on hypoglycemia incidence, with direction unspecified.

    In plain wordsIn Japanese patients receiving dulaglutide, sulfonylurea use most affected low-blood-sugar incidence, but the abstract did not state the direction.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedHypoglycemia and sulfonylurea use
    Study

    n: not reported in source

    Comparator
    Other patient characteristics
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Concomitant use of sulfonylureas had the greatest effect on the incidence of hypoglycemia.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.